Daré Bioscience, Inc.
DARE
$2.88
-$0.04-1.37%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 173.12% | -103.52% | -95.83% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 173.12% | -103.52% | -95.83% | -- | -- |
| Cost of Revenue | -31.65% | -34.04% | 0.00% | 0.00% | 13,344.80% |
| Gross Profit | 32.22% | 27.68% | -98.29% | 89.60% | -13,307.60% |
| SG&A Expenses | -13.53% | -32.45% | -24.31% | -16.18% | -19.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.63% | -21.46% | -49.74% | -17.88% | -28.04% |
| Operating Income | 23.93% | -8.38% | 44.25% | 18.13% | 28.15% |
| Income Before Tax | 35.19% | -8.87% | 43.34% | 247.35% | 16.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.19% | -8.87% | 43.34% | 247.35% | 16.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.19% | -8.87% | 43.34% | 247.35% | 16.00% |
| EBIT | 23.93% | -8.38% | 44.25% | 18.13% | 28.15% |
| EBITDA | 26.43% | -8.47% | 44.30% | 18.22% | 28.20% |
| EPS Basic | 38.02% | 0.95% | 49.63% | 226.13% | 28.53% |
| Normalized Basic EPS | 38.03% | -14.37% | 49.62% | 226.12% | 28.53% |
| EPS Diluted | 38.02% | 1.06% | 49.63% | 224.59% | 28.53% |
| Normalized Diluted EPS | 38.03% | -14.37% | 49.62% | 225.16% | 28.53% |
| Average Basic Shares Outstanding | 4.57% | 9.92% | 12.48% | 16.82% | 17.54% |
| Average Diluted Shares Outstanding | 4.57% | 9.92% | 12.48% | 17.72% | 17.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |